Literatur
-
1
Willemze R, Jaffe E S, Burg G et al.
WHO-EORTC classification for cutaneous lymphomas.
Blood.
2005;
105
3768-3785
-
2
Assaf C, Gellrich S, Steinhoff M et al.
Cutaneous lymphomas in Germany: an analysis of the Central
Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG).
J Dtsch Dermatol Ges.
2007;
5
662-668
-
3
Dummer R, Stadler R, Sterry W.
Cutaneous lymphomas.
J Dtsch Dermatol Ges.
2007;
5
605-617
-
4
Senff N J, Noordijk E M, Kim Y H European Organization for Research and Treatment of
Cancer; International Society for Cutaneous Lymphoma et al..
European Organization for Research and Treatment of Cancer
and International Society for Cutaneous Lymphoma consensus recommendations for
the management of cutaneous B-cell lymphomas.
Blood.
2008;
112
1600-1609
-
5
Burg G, Kempf W, Cozzio A et al.
Cutaneous malignant lymphomas: update 2006.
J Dtsch Dermatol Ges.
2006;
4
914-933
-
6
Fink-Puches R, Zenahlik P, Bäck B et al.
Primary cutaneous lymphomas: applicability of current
classification schemes (European Organization for Research and Treatment of
Cancer, World Health Organization) based on clinicopathologic features observed
in a large group of patients.
Blood.
2002;
99
800-805
-
7
Child F J, Woollons A, Price M L et al.
Multiple cutaneous immunocytoma with secondary anetoderma: a
report of two cases.
Br J Dermatol.
2000;
143
165-170
-
8
de Leval L, Harris N L, Longtine J et al.
Cutaneous b-cell lymphomas of follicular and marginal zone
types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and
classification.
Am J Surg Pathol.
2001;
25
732-741
-
9 Swerdlow S H, Campo E, Harris N L et al. World Health Organization classification of tumours of
haematopoietic and lymphoid tissues.. Lyon: IARC Press; 2008
-
10
Grange F, Petrella T, Beylot-Barry M et al.
Bcl-2 protein expression is the strongest independent
prognostic factor of survival in primary cutaneous large B-cell lymphomas.
Blood.
2004;
103
3662-3668
-
11
Hallermann C, Niermann C, Fischer R J et al.
New prognostic relevant factors in primary cutaneous diffuse
large B-cell lymphomas.
J Am Acad Dermatol.
2007;
56
588-597
-
12
Ponzoni M, Ferreri A J, Campo E et al.
Definition, diagnosis, and management of intravascular large
B-cell lymphoma: proposals and perspectives from an international consensus
meeting.
J Clin Oncol.
2007;
25
3168-3173
-
13
Koens L, Vermeer M H, Willemze R et al.
IgM expression on paraffin sections distinguishes primary
cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle
center lymphoma.
Am J Surg Pathol.
2010;
34
1043-1048
-
14
Kim Y H, Willemze R, Pimpinelli N et al.
TNM classification system for primary cutaneous lymphomas
other than mycosis fungoides and Sezary syndrome: a proposal of the
International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma
Task Force of the European Organization of Research and Treatment of Cancer
(EORTC).
Blood.
2007;
110
479-484
-
15
Cronin C G, Swords R, Truong M T et al.
Clinical utility of PET/CT in lymphoma.
Am J Roentgenol.
2010;
194
W91-W103
-
16
Senff N J, Willemze R.
The applicability and prognostic value of the new TNM
classification system for primary cutaneous lymphomas other than mycosis
fungoides and Sézary syndrome: results on a large cohort of primary
cutaneous B-cell lymphomas and comparison with the system used by the Dutch
Cutaneous Lymphoma Group.
Br J Dermatol.
2007;
157
1205-1211
-
17
Stadler R, Assaf C, Klemke C D et al.
Short German guidelines: cutaneous lymphomas.
J Dtsch Dermatol Ges.
2008;
6 (Suppl. 1)
S25-S31
-
18
Cerroni L, Zöchling N, Pütz B et al.
Infection by Borrelia burgdorferi and cutaneous B-cell
lymphoma.
J Cutan Pathol.
1997;
24
457-461
-
19
Goodlad J R, Davidson M M, Hollowood K et al.
Primary cutaneous B-cell lymphoma and Borrelia burgdorferi
infection in patients from the Highlands of Scotland.
Am J Surg Pathol.
2000;
24
1279-1285
-
20
Li C, Inagaki H, Kuo T T et al.
Primary cutaneous marginal zone B-cell lymphoma: a molecular
and clinicopathologic study of 24 asian cases.
Am J Surg Pathol.
2003;
27
1061-1069
-
21
Wood G S, Kamath N V, Guitart J et al.
Absence of Borrelia burgdorferi DNA in cutaneous B-cell
lymphomas from the United States.
J Cutan Pathol.
2001;
28
502-507
-
22
Senff N J, Hoefnagel J J, Jansen P M et al.
Reclassification of 300 primary cutaneous B-Cell lymphomas
according to the new WHO-EORTC classification for cutaneous lymphomas:
comparison with previous classifications and identification of prognostic
markers.
J Clin Oncol.
2007;
25
1581-1587
-
23
Kodama K, Massone C, Chott A et al.
Primary cutaneous large B-cell lymphomas: clinicopathologic
features, classification, and prognostic factors in a large series of
patients.
Blood.
2005;
106
2491-2497
-
24
Fink-Puches R, Wolf I H, Zalaudek I et al.
Treatment of primary cutaneous B-cell lymphoma with
rituximab.
J Am Acad Dermatol.
2005;
52
847-853
-
25
Mian M, Marcheselli L, Luminari S et al.
CLIPI: a new prognostic index for indolent cutaneous B cell
lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG
11).
Ann Hematol.
[in press]
-
26
Pulini S, Rupoli S, Goteri G et al.
Efficacy and safety of pegylated liposomal doxorubicin in
primary cutaneous B-cell lymphomas and comparison with the commonly used
therapies.
Eur J Haematol.
2009;
82
184-193
-
27
Mounier N, Briere J, Gisselbrecht C et al.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated
resistance to chemotherapy in elderly patients with diffuse large B-cell
lymphoma (DLBCL).
Blood.
2003;
101
4279-4284
-
28
Skvortsova I, Skvortsov S, Popper B A et al.
Rituximab enhances radiation-triggered apoptosis in
non-Hodgkin’s lymphoma cells via caspase-dependent and –
independent mechanisms.
J Radiat Res.
(Tokyo)
2006;
47
183-196
-
29
Skvortsova I, Popper B A, Skvortsov S et al.
Pretreatment with rituximab enhances radiosensitivity of
non-Hodgkin’s lymphoma cells.
J Radiat Res.
(Tokyo)
2005;
46
241-248
Dr. med. Oliver Inhoff
Funktionsoberarzt
Hautklinik/Hauttumorzentrum
Rheinpfalz
Klinikum Ludwigshafen
Bremserstr. 79
67063 Ludwigshafen
eMail: inhoffo@klilu.de
